Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...

We recently published a list of Friday’s 10 Worst Performing Stocks. In this article, we are going to take a look at where ...

Shares of Abbott Laboratories and Reckitt Benckiser fell Friday after a judge ruled a new trial could be heard involving a case on their infant formula products that had already seen a ruling in their ...

a debilitating intestinal disease that can cause bloating, vomiting and diarrhea in premature babies. A previous ruling last July had found Abbott Labs failed to adequately warn of this risk.

Back in October, a jury found North Chicago-based Abbott and Reckitt’s formula subsidiary Mead Johnson not responsible for a ...

Abbott Laboratories and Reckitt Benckiser Group Plc shares fell as a judge ordered a new trial after rejecting a verdict that ...

医疗保健巨头Abbott Laboratories的股价本周攀升至52周新高，达到USD 134.46。这家市值2330亿美元、以多元化医疗设备和保健产品闻名的公司在过去六个月内取得了20.75%的回报，展现出显著实力。根据InvestingPro分析，该公司目前的交易价格略高于其公允价值。过去一年内12.83%的涨幅令投资者备受鼓舞，这反映了市场对Abbott强大产品管线和有效驾驭复杂医疗保健环 ...

Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

Key Takeaways Infant formula makers Abbott and Reckitt saw their stocks decline Friday after a judge ruled plaintiffs could ...

Abbott将在临床试验的多个方面提供支持，包括规划、试验点选择以及分享其HeartMate 3™的使用经验。在LVAD市场中，Abbott的HeartMate 3™是目前美国唯一可用的设备，该市场在2023年估值为USD 11亿，预计到2032年将达到USD 24亿。

The ruling overturned a previous verdict related to an infant formula case and has implications for both Abbott and Reckitt, ...

Abbott (ABT) in October 2024 won the Whitfield case, though the plaintiffs appealed the Whitfield verdict and on Thursday, the judge granted a ...